Molecure S.A. (WSE:MOC)

Market Cap	129.59M -14.4%
Revenue (ttm)	5.86M +459.1%
Net Income	-24.42M
EPS	-1.06
Shares Out	20.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,829
Average Volume	35,244
Open	6.28
Previous Close	6.29
Day's Range	5.85 - 6.28
52-Week Range	5.15 - 9.44
Beta	0.90
RSI	30.57
Earnings Date	Apr 30, 2026

About Molecure

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-4...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 71
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: MOC

Financial Performance

In 2024, Molecure's revenue was 2.92 million, a decrease of -20.08% compared to the previous year's 3.65 million. Losses were -31.29 million, 10.3% more than in 2023.